Premium
TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T‐CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST‐HOC ANALYSIS OF THE MAVORIC STUDY
Author(s) -
Kim Y.H.,
OrtizRomero P.L.,
Pro B.,
Sokol L.,
Scarisbrick J.,
Musiek A.,
Vermeer M.,
Dummer R.,
Halwani A.,
Fierro M.,
Moriya J.,
Leoni M.,
Bagot M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.95_2630
Subject(s) - medicine , mycosis fungoides , cutaneous t cell lymphoma , post hoc analysis , vorinostat , gastroenterology , clinical endpoint , dermatology , oncology , clinical trial , lymphoma , biochemistry , chemistry , histone deacetylase , gene , histone